Axon Enterprise, Inc $AXON Shares Acquired by U.S. Capital Wealth Advisors LLC

Key Points

• U.S. Capital Wealth Advisors LLC increased its stake in Axon Enterprise, Inc by 26.4% during the 2nd quarter, bringing their total holdings to approximately $1.62 million.
• Axon Enterprise reported a significant earnings beat with $2.12 EPS for the latest quarter, surpassing estimates by $0.58 and showing a 32.6% year-over-year revenue growth.
• Analysts remain optimistic, with fourteen issuing a Buy rating for Axon and a consensus price target of $837.69.

U.S. Capital Wealth Advisors LLC boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 26.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,961 shares of the biotechnology company's stock after buying an additional 410 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Axon Enterprise were worth $1,624,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Park Avenue Securities LLC purchased a new position in shares of Axon Enterprise in the 2nd quarter valued at about $3,994,000. Sowell Financial Services LLC raised its stake in shares of Axon Enterprise by 56.6% during the 2nd quarter. Sowell Financial Services LLC now owns 6,310 shares of the biotechnology company's stock worth $5,224,000 after buying an additional 2,280 shares during the period. Arthur M. Cohen & Associates LLC lifted its position in shares of Axon Enterprise by 3.1% during the 2nd quarter. Arthur M. Cohen & Associates LLC now owns 2,378 shares of the biotechnology company's stock valued at $1,969,000 after buying an additional 71 shares in the last quarter. Compass Ion Advisors LLC acquired a new stake in Axon Enterprise in the 2nd quarter valued at $830,000. Finally, First PREMIER Bank increased its holdings in Axon Enterprise by 107.5% in the 2nd quarter. First PREMIER Bank now owns 222 shares of the biotechnology company's stock worth $184,000 after acquiring an additional 115 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $777.58 on Wednesday. The firm has a market cap of $61.04 billion, a PE ratio of 192.00, a price-to-earnings-growth ratio of 28.48 and a beta of 1.40. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52 week low of $388.36 and a 52 week high of $885.91. The business's fifty day simple moving average is $761.12 and its 200-day simple moving average is $698.98.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same period in the previous year, the firm earned $1.20 EPS. Axon Enterprise's revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on AXON. Craig Hallum raised shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price objective on the stock in a report on Tuesday, August 5th. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an "overweight" rating in a research report on Friday, July 11th. Zacks Research cut Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Bank of America boosted their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Finally, Northland Securities set a $800.00 target price on Axon Enterprise in a report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $837.69.

Insiders Place Their Bets

In other news, Director Jeri Williams sold 100 shares of the company's stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the transaction, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. This represents a 6.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 870 shares of Axon Enterprise stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $773.25, for a total transaction of $672,727.50. Following the completion of the sale, the chief financial officer owned 113,022 shares of the company's stock, valued at $87,394,261.50. This trade represents a 0.76% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,932 shares of company stock worth $34,408,816. Insiders own 5.70% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.